News

TB R&D Weekly Update: Podcast Interview with Dr. Edward Nardell

Dr. Edward Nardell, Partners in Health
Dr. Edward Nardell, Partners in Health

Listen to Edward Nardell Podcast

Summary: This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis; trained in pulmonary medicine at Massachusetts General Hospital with additional research training at Boston University School of Medicine. His principal academic appointment is as associate professor of medicine, Harvard Medical School, with secondary parallel appointments in the Department of Global Health and Social Medicine and Harvard School of Public Health. In 2002 he joined Partners In Health as Director of Tuberculosis Research.

His research interests include the control of multidrug-resistant tuberculosis (MDR-TB) in Peru, Russia, and other high-burden countries, with a special research interest in airborne TB transmission and control. Dr. Nardell is currently conducting a research project in South Africa studying the transmission of MDR-TB using large numbers of guinea pigs to quantify the infectiousness of MDR-TB patients and the effectiveness of various control interventions, including ultraviolet germicidal irradiation. (Click here to view full bio) During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.

Additional TB R&D News:

CDC: Latent TB treatment may now be done in 3 months

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

New Findings Reported from Georgia Institute of Technology Describe Advances in Microbial Drug Resistance

More News
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...